ROME (ITALPRESS) – A conference organized on the occasion of World Diabetes Day, dedicated to new perspectives in the prevention and management of pediatric type 1 diabetes, was held today in Rome at the Cardinal Colonna Gallery. Italy is confirmed as an international protagonist with the recent Law No. 130/2023, the first to introduce a national pediatric screening for the early diagnosis of type 1 diabetes and celiac disease. The event, organized with the nonconditional contribution of Sanofi, Roche, Movi, and Revvity, involved leading figures from institutions and the medical scene.Institutional greetings were opened by Giorgio Mulè, Vice President of the Chamber of Deputies, Paola Frassinetti, Undersecretary of State at the Ministry of Education and Merit, and Roberto Marti, President of the 7th Commission. “Law No. 130,” declares Giorgio Mulè, “represents a solemn commitment to the new generations, ensuring them timely access to early diagnosis of type 1 diabetes and celiac disease. This measure places Italy at the forefront of prevention, promoting a culture of awareness and knowledge of the disease. With such a vision, our country builds a community that is increasingly inclusive and attentive to the needs of the youngest age groups. “Among the speakers, Valentino Cherubini, president of the Italian Society of Pediatric Endocrinology and Diabetology, illustrated the importance of early diagnosis and screening: “The adoption of screening allows for the precise identification of children at risk. Therefore, the creation of a registry of individuals positive for specific antibodies is essential to improve clinical monitoring and management strategies, thus helping to reduce the incidence of diabetic ketoacidosis.” Confirming the relevance of the Law, Raffaella Buzzetti, President of the Italian Society of Diabetology, emphasized the need for the new diagnostic classification codes: “I consider the introduction of new specific codes for pre-symptomatic conditions of Type 1 Diabetes to be fundamental. Indeed, this would make it possible to cover the services needed to accompany, in the follow-up and monitoring phase, the person with antibody positivity for Type 1 diabetes, and therefore with presymptomatic disease. These codes would, therefore, allow access to preventive interventions and monitoring under an agreement with the NHS and therefore without economic barriers, strengthening the ability of the health care system to act from the prodromal stages of the disease. “Representing the patient associations was Stefano Nervo, president of Diabetes Italia Onlus, who highlighted the importance of technological innovation in support of the management of type 1 diabetes, with specific reference to pediatric age: “The latest generation technologies allow continuous monitoring and optimized management of therapy, improving the quality of life of patients. It is essential to increase investment in research to ensure access to advanced tools, fostering sustainable disease management that meets the needs of patients and families.”The conference, sponsored by the Italian Society of Pediatric Endocrinology and Diabetology, the Italian Society of Diabetology, the Association of Diabetes Physicians, the Italian Federation of Pediatric Physicians, the Italian Diabetes Foundation ETS and Diabetes Italia Onlus, reaffirmed the importance of a multidisciplinary approach, in which institutions, companies, research centers, pediatricians and families collaborate in an integrated system of prevention and care.-press office photo Esperia Advocacy-(ITALPRESS)
